Article info

Download PDFPDF

Original research
Tolerance and efficacy of targeted therapies prescribed for off-label indications in refractory systemic autoimmune diseases: data of the first 100 patients enrolled in the TATA registry (TArgeted Therapy in Autoimmune Diseases)

Authors

  1. Correspondence to Dr Jacques-Eric Gottenberg; jacques-eric.gottenberg{at}chru-strasbourg.fr
View Full Text

Citation

Gottenberg J, Chaudier A, Allenbach Y, et al
Tolerance and efficacy of targeted therapies prescribed for off-label indications in refractory systemic autoimmune diseases: data of the first 100 patients enrolled in the TATA registry (TArgeted Therapy in Autoimmune Diseases)

Publication history

  • Received March 17, 2022
  • Accepted July 19, 2022
  • First published November 1, 2022.
Online issue publication 
June 27, 2023
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.